Abstract:Damage to DNA is caused by ionizing radiation, genotoxic chemicals or collapsed replication forks. When DNA is damaged or cells fail to respond, a mutation that is associated with breast or ovarian cancer may occur. Mammalian cells control and stabilize the genome using a cell cycle checkpoint to prevent damage to DNA or to repair damaged DNA. Checkpoint kinase 2 (Chk2) is one of the important kinases, which strongly affects DNA-damage and plays an important role in the response to the breakage of DNA double-strands and related lesions. Therefore, this study concerns Chk2. Its purpose is to find potential inhibitors using the pharmacophore hypotheses (PhModels) and virtual screening techniques. PhModels can identify inhibitors with high biological activities and virtual screening techniques are used to screen the database of the National Cancer Institute (NCI) to retrieve compounds that exhibit all of the pharmacophoric features of potential inhibitors with high interaction energy. Ten PhModels were generated using the HypoGen best algorithm. The established PhModel, Hypo01, was evaluated by performing a cost function analysis of its correlation coefficient (r), root mean square deviation (RMSD), cost difference, and configuration cost, with the values 0.955, 1.28, 192.51, and 16.07, respectively. The result of Fischer’s cross-validation test for the Hypo01 model yielded a 95% confidence level, and the correlation coefficient of the testing set (rtest) had a best value of 0.81. The potential inhibitors were then chosen from the NCI database by Hypo01 model screening and molecular docking using the cdocker docking program. Finally, the selected compounds exhibited the identified pharmacophoric features and had a high interaction energy between the ligand and the receptor. Eighty-three potential inhibitors for Chk2 are retrieved for further study.

Targeting the checkpoint kinases: chemosensitization versus chemoprotection

Drug Discovery Targeting Chk1 and Chk2 Kinases.

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Targeting DNA checkpoint kinases in cancer therapy.

BRD7 Suppresses Tumor Chemosensitivity to CHK1 Inhibitors by Inhibiting USP1-mediated Deubiquitination of CHK1

Functions and Inhibitors of CHK1 in Cancer Therapy

Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale

Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair

Checkpoint Kinase‑1 Inhibition and Etoposide Exhibit a Strong Synergistic Anticancer Effect on Chronic Myeloid Leukemia Cell Line K562 by Impairing Homologous Recombination DNA Damage Repair

The Role of CHK1 Varies with the Status of Oestrogen-receptor and Progesterone-receptor in the Targeted Therapy for Breast Cancer.

DNA damage checkpoint kinases in cancer

Design checkpoint kinase 2 inhibitors by pharmacophore modeling and virtual screening techniques.

Perspectives on the Combination of Radiotherapy and Targeted Therapy with DNA Repair Inhibitors in the Treatment of Pancreatic Cancer.

Dual Induction of Apoptosis and Senescence in Cancer Cells by Chk2 Activation: Checkpoint Activation As a Strategy Against Cancer.

DNA Damage Checkpoint Recovery and Cancer Development

Guarding against digestive-system cancers: Unveiling the role of Chk2 as a potential therapeutic target

The Potential for Targeting G2/M Cell Cycle Checkpoint Kinases in Enhancing the Efficacy of Radiotherapy

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment

Co-abrogation of Chk1 and Chk2 by potent oncolytic adenovirus potentiates the antitumor efficacy of cisplatin or irradiation

Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer

The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.